Late detection
Haemoglobin-led pathways often act after anaemia is already present.
Impact
Earlier insight where screening already happens.
Iron deficiency affects energy, cognition, pregnancy, recovery, and long-term health. ZAWADI explores a simpler, earlier pathway — without starting with a blood draw.
The unmet need
Iron deficiency can begin before anaemia is obvious.
Many pathways depend on blood collection, laboratory infrastructure, and markers that identify the problem only after it has progressed.
Friction at the frontline
Blood draws and lab loops limit repeat screening in busy antenatal clinics.
Missed prevention window
Earlier iron restriction is actionable — but rarely visible in decentralised care.
The timing gap
ZPP rises while iron stores are still falling.
That is the prevention window ZAWADI is built to observe — before anaemia begins.
Intended settings
Clinics, outreach, and decentralised care.
Designed around the realities of point-of-care screening — not a central lab workflow.
Antenatal clinics
Repeatable screening alongside existing ANC visits.
Community outreach
Portable form factor for programmes beyond fixed facilities.
Women's health pathways
Built at the intersection of diagnostics and maternal health.
Treatment monitoring
Future expansion toward longitudinal iron-status insight.
Beachhead
Start where screening already happens.
Rwanda antenatal care first — then expand across women's health and treatment monitoring as evidence allows.
Beachhead
Rwanda ANC
~330,000 antenatal care visits per year — a concentrated, routine screening touchpoint.
Expand
Community & adolescent screening
Same reader, same consumable, new cohorts reached through existing frontline structures.
Deepen
Postpartum & chronic monitoring
Repeatable measurement makes treatment response trackable over time.
Scale
Sub-Saharan Africa & South Asia
Regions where iron deficiency burden and ANC infrastructure overlap most strongly.
Development-stage notice: ZAWADI is under active validation. Not a diagnostic substitute. Regulatory status: Research and development programme — not submitted for regulatory clearance and not offered for clinical diagnosis or commercial use.